

Short Report

A new way to produce hyperketonemia: Use of ketone ester in a case of Alzheimer's disease

Mary T. Newport^a, Theodore B. VanItallie^b, Yoshihiro Kashiwaya^c, Michael Todd King^d,
Richard L. Veech^{d,*}

^aSpring Hill Neonatology, Inc, Spring Hill, FL, USA

^bDepartment of Medicine, St. Luke's Hospital, New York, NY, USA

^cDivision of Neurology, Tominaga Hospital, Osaka, Japan

^dLaboratory of Metabolic Control, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA

Abstract

Background: Providing ketone bodies to the brain can bypass metabolic blocks to glucose utilization and improve function in energy-starved neurons. For this, plasma ketones must be elevated well above the ≤ 0.2 mM default concentrations normally prevalent. Limitations of dietary methods currently used to produce therapeutic hyperketonemia have stimulated the search for better approaches.

Method: Described herein is a new way to produce therapeutic hyperketonemia, entailing prolonged oral administration of a potent ketogenic agent—ketone monoester (KME)—to a patient with Alzheimer's disease dementia and a pretreatment Mini-Mental State Examination score of 12.

Results: The patient improved markedly in mood, affect, self-care, and cognitive and daily activity performance. The KME was well tolerated throughout the 20-month treatment period. Cognitive performance tracked plasma β -hydroxybutyrate concentrations, with noticeable improvements in conversation and interaction at the higher levels, compared with predose levels.

Conclusion: KME-induced hyperketonemia is robust, convenient, and safe, and the ester can be taken as an oral supplement without changing the habitual diet.

Published by Elsevier Inc. on behalf of The Alzheimer's Association.

Keywords:

Ketone bodies; β -Hydroxybutyrate; Pyruvate dehydrogenase; Brain insulin resistance; Fasting; Ketogenic diet; Medium-chain triglyceride; Ketone monoester

1. Background

Impairment of the brain's glucose utilization is an early feature of Alzheimer's disease (AD) and may contribute to its causation and progression [1,2]. In patients with preclinical AD, fluorodeoxyglucose positron emission tomography discloses a consistent pattern of reduction in the cerebral metabolic rate of glucose (CMRglu) in the posterior cingulate, parietal, temporal, and prefrontal locations [3]. Clinical AD symptoms almost never occur

without such CMRglu decreases [3], which may be associated with local brain insulin resistance [4].

To the extent impairment of glucose utilization contributes to AD's pathogenesis, providing the AD brain with sufficient ketone bodies (KBs)—the brain's principal alternative fuel during prolonged fasting [5,6]—would likely mitigate the energy deficit, as shown in Fig. 1.

However, to deliver enough KB-derived energy to glucose-deprived parts of the AD brain, it is necessary to raise plasma KB levels significantly above the ≤ 0.2 mM default concentrations customary in metabolically normal individuals [6,7]. As shown in Fig. 1, KB-derived acetyl CoA enters the pathway to the Krebs (tricarboxylic acid) cycle distal to the rate-limiting mitochondrial enzyme, pyruvate dehydrogenase (PDH), thus bypassing blocks in glucose utilization such as that caused by the inhibiting effect of insulin resistance on PDH activity [8,9].

Dr. Newport, Dr. VanItallie, and M.T. King have no financial interests in ketone monoester. Dr. VanItallie is a minority shareholder in a company that produces a food product containing medium-chain fatty acids. Dr. Veech has patent right from invention determined by NIH and DHHS standards.

*Corresponding author. Tel.: +1-301-443-4620; Fax: +1-301-443-0930.

E-mail address: rlvveech@comcast.net




Fig. 1. Glucose and the ketone bodies, β -hydroxybutyrate (β HB) and acetoacetate (AcAc), enter neurons via different plasma membrane transporters, namely, glucose transporter 3 (GLUT3) and (ordinarily) monocarboxylate transporter 2 (MCT2), respectively. After cytosolic glycolysis, glucose-derived pyruvate enters mitochondria, undergoing oxidative decarboxylation by pyruvate dehydrogenase (PDH). The resulting acetyl CoA is then metabolized via the Krebs cycle. Inhibition of PDH activity (i.e., as caused by local insulin resistance) can reduce availability to mitochondria of energy-generating substrate, which may compromise neuronal function. In contrast, AcAc (derived in part from circulating β HB) is converted to acetyl CoA distal to the pyruvate \rightarrow acetyl CoA step, thereby circumventing possible blocks to glucose metabolism at, or proximal to, that step.

Plasma ketone levels most expedient for rescue of still viable, energy-starved parts of the AD brain are unknown; however, during hyperketonemia, the rate-limiting step for KB utilization is their transport into brain, with the utilization rate increasing nearly proportionally with plasma KB concentration [10]. In eight healthy young adults, daily administration of 20 g of medium-chain triglyceride (MCTG) for 1 week, followed by 30 g/d for 3 weeks, raised plasma KB levels to a mean value throughout the study day of 0.29 mM, with a peak level of 0.48 mM. This degree of hyperketonemia was estimated to contribute up to 9% of brain energy metabolism [7].

2. Established methods for inducing therapeutic hyperketonemia

Established methods for inducing therapeutic hyperketonemia have entailed adherence to a ketogenic diet (KD) [11] and/or repetitive ingestion of MCTG [12]. Successful adherence to the very high-fat, very low-carbohydrate classical KD requires strong motivation in patients and caregivers. Liberalized versions may provide clinical benefit at lower plasma ketone levels [11].

Prolonged KD consumption may increase levels of atherogenic lipids and produce other adverse effects [6,11]. After 8 weeks on a very low-carbohydrate diet (5%–10% of calories), a group of elderly individuals with mild cognitive impairment (MCI) exhibited improved verbal memory performance ($P = .01$) [13].

MCTG users can elevate plasma ketone levels while continuing their usual diet. In a cohort of patients with

MCI and AD given 20 g of MCTG/d, β -hydroxybutyrate (β HB) concentrations rose from ~ 0.09 mM (before dose) to 0.3 to 0.4 mM (2 hours after dose). During hyperketonemia, cognitive performance significantly improved—but only among subjects who were apolipoprotein E (*APOE*) $\epsilon 4$ allele negative [12]. The highest KB levels appeared to confer most benefit. About 12.5% of the subjects discontinued participation because of minor gastrointestinal side effects.

3. A novel direct approach to the production of therapeutic hyperketonemia

Herein, we report the first use, in a patient with younger onset sporadic AD, of a potent ketogenic agent, (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (referred to herein as ketone monoester [KME]) [14]. KME has undergone extensive animal [15] and human toxicity tests [14] and meets Food and Drug Administration generally recognized as safe standards. KME improves cognitive performance and reduces amyloid- β and tau deposition in cognition-relevant areas in a mouse AD model [16].

After ingestion, KME is fully hydrolyzed in the small intestine, yielding (1) β HB, carried to the systemic circulation, and (2) 1,3-butanediol, metabolized in liver to acetoacetate and β HB [15].

Study of KME's kinetics, safety, and tolerability in 27 men and 27 women found that compared with the inconvenience of preparing and consuming a KD, KME ingestion is a safe and simple method for temporarily elevating the

plasma KB level to c. 4.5 mM within 1 to 2 hours after ingestion of 714 mg/kg [14].

4. Clinical response of a patient with AD dementia to KME treatment

4.1. The patient

The patient is a 63-year-old Caucasian male, former accountant, with younger onset, sporadic AD for 12 years. In 2001, at the age of 51 years, he began to complain of short-term memory loss, initially attributed to depression. The condition inexorably worsened and, during 2006, he had to give up his job and stop driving. By then, he was displaying characteristic features of AD dementia, including increasingly severe memory loss, poor concentration and organization, misplacing important items, inability to carry out activities of daily living, and inability to spell and read. Between 2004 and 2008, his Mini-Mental State Examination (MMSE) score declined from 23 to 12. Brain magnetic resonance imaging (MRI) on August 18, 2004, was reported normal; however, MRI on June 16, 2008, showed diffuse involuntional changes of frontal and parietal lobes and moderate left-sided and severe right-sided atrophy of amygdala and hippocampus, consistent with AD. He was found to be *APOE* ϵ 4 positive.

4.2. Initial treatment with ketogenic medium-chain (C8 [caprylic] and C10 [capric]) fatty acids

Because of published information [17] suggesting that MCTG-induced increases in plasma ketone levels might benefit AD patients, the patient was initially placed, on May 21, 2008, on 35-mL coconut oil (CO) once daily (CO contains ~15% ketogenic medium-chain fatty acid [MCFA]). Then, over several months, MCTG was added and increased gradually to a 4:3 mixture with CO, eventually reaching 165 mL/d divided into 3 to 4 servings. Use of the MCTG/CO mixtures as dietary supplements was associated with rapid improvement in the patient's personality, mood, and tremor. MMSE improved from 12, measured on May 9, 2008, to a high of 20, 75 days later. During the ensuing year, additional gradual improvement occurred in gait, social participation, word finding, and recall of recent events. Thus, during MCFA treatment for 20 months, the patient showed considerable cognitive improvement (Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog] rose 6 points and ADLs [Activities of Daily Living] rose 14 points), followed by stabilization. MRI findings on April 28, 2010, were no different from those on June 16, 2008. Hence, during the 2-year period of MCTG/CO treatment, the patient's brain remained MRI stable.

During the winter of 2010, while participating in a cross-over clinical trial of the γ -secretase inhibitor, semagacestat, the patient retrogressed when shifted from placebo to drug. The deterioration, which presumably resulted from semagacestat-induced collateral damage to other proteins

affecting neurocognitive function [18], persisted after the drug was stopped. It is now known that the patient was on placebo during at least the initial 12 months of the study. He discontinued participation in the study on March 1, 2010, owing to new problems appearing in the prior month, including poor wound healing, fainting, elevated creatine phosphokinase (noncardiac), a respiratory infection, and outbreak of fever blisters. Also, throughout February and March 2010, he became increasingly depressed and began to experience confusion with images in the mirror and his whereabouts in the home. He began wandering, lost interest in yard and housework, and required step-by-step instruction and considerable assistance to dress and complete hygiene-related tasks.

4.3. Clinical response to treatment with KME

As the patient's condition worsened, his wife/caregiver, a neonatology specialist, became increasingly desperate for a remedy. Searching for new treatments, she found several articles [6,19,20] suggesting that, in certain AD patients, ketone ester-induced elevation of plasma KB to levels approximating to those obtained during a fast might prove more effective than the lower concentrations achievable by MCTG administration [7,12].

On April 29, 2010, with his full cooperation and consent, the patient was started at home on orally administered KME. Throughout KME treatment, the patient remained on his usual diet and also continued to take the MCTG/CO mixture, as described in Section 4.2. (KME was always taken mixed with soda-flavored syrups [25% syrup, 25% KME, and 50% water] to help mask its disagreeable taste. The KME mixture was invariably well tolerated.)

During the first two KME days, the patient received 21.5 g thrice daily. Thirty minutes of video taken between 2 and 3 hours after the first dose of KME demonstrate a marked improvement in mood and the ability to recite and write out the complete alphabet, which he had been unable to do for many months. The next morning, he spontaneously chose clothes and dressed himself—also a new development. On the third day of KME treatment, the amount administered was increased to three 28.7 g servings/d. After serving-size increase, he began to initiate and complete many other activities without prompting or assistance.

These included showering, shaving, brushing teeth, finding his way around the house, choosing and ordering food from a menu, and distributing utensils from the dishwasher. These activities had not been observed for months before KME was started. Abstract thinking, insight, and a subtle sense of humor returned to his conversation. In his own assessment of his response to KME, he stated that he felt “good,” had “more energy,” and was “happier.” He also found it “easier to do things”—which coincided with the caregiver's observations.

After 6 to 8 weeks of taking 28.7 g of the KME thrice daily, he began to exhibit improvement in memory retrieval,

spontaneously discussing events that occurred up to a week earlier. He was again able to perform more complex tasks such as vacuuming, washing dishes by hand, and yard work.

Plasma β HB levels were measured occasionally to assess KME plasma β HB dose-response relationships (Fig. 2). Noticeable improvements in performance (conversation and interaction) were observed at higher postdose β HB levels compared with predose values.

Of a battery of commonly ordered blood chemistry tests done on the patient before and during KME treatment, the only noteworthy changes were in certain plasma lipids. Over 20 months, the total cholesterol level fell from a pre-KME mean ($n = 2$) of 244 to 163 mg/dL. The high-density lipoprotein cholesterol level fell from 85 to 68 mg/dL and low-density lipoprotein cholesterol from 145 to 81 mg/dL.

5. Discussion

The fact that relatively high plasma KB levels (6–8 mM) can be maintained indefinitely when KME is ingested at 3- to




Fig. 2. β -Hydroxybutyrate (β HB) concentrations rose to 3 to 7 mM 1 hour after ingestion of ketone monoester (KME) in three different doses, 25, 35, and 50 g, taken on separate days. The peak levels measured are in the range of those obtained during adherence to the classical ketogenic diet and are about 10-fold the concentrations achievable by medium-chain triglyceride (MCTG) administration. Because no more than two β HB measurements were made during the first 2 hours after KME ingestion, higher levels might have been reached that were not detected. The findings suggest that substantially elevated blood ketone concentrations can be maintained throughout the day if KME is taken every 3 to 4 hours. Precision Xtra Glucose and Ketone Monitoring System (Abbott Diabetes Care, Inc., Alameda, CA, USA) was used to measure β HB levels in capillary blood samples. Acetoacetate (AcAc), ordinarily a minor fraction of total blood ketones, was not measured.

4-hour intervals may raise questions about the long-term safety of this degree of hyperketonemia. Before KME became available, the only way to obtain comparable plasma KB elevations was by prolonged fasting [5] or strict adherence to a very high-fat, very low-carbohydrate KD [11]. Because these methods have confounding metabolic side effects such as dehydration, urate nephrolithiasis, substantial weight changes, and amenorrhea [21] neither can serve as a satisfactory test for the long-term safety of KME-induced hyperketonemia. Nevertheless, three severely obese inpatients who sustained mean KB levels of ~ 8 mM while undergoing 5 to 6 weeks of starvation for weight loss did not exhibit adverse clinical effects attributable to the protracted hyperketonemia [5].

In rare instances, hyperketonemia, by reducing renal uric acid clearance, can raise plasma uric acid to levels sufficient to precipitate a flare in gout-susceptible individuals [22]. Drugs that inhibit uric acid synthesis can prevent this complication.

At present, there is no evidence that, by itself, chronic hyperketonemia (at concentrations of ~ 8 mM) may be clinically unsafe. However, if valid safety issues arise, they should be considered in the light of a possible beneficial effect of KME on such devastating diseases as AD and on disabling convulsions in infants and children who are refractory to antiseizure medications [23].

Given the report by Henderson et al. [12] indicating that the *APOE* $\epsilon 4$ -positive subjects in their study failed to show statistically significant improvement in their ADAS-Cog scores in response to MCTG treatment, it is noteworthy that the patient, although *APOE* $\epsilon 4$ -positive, exhibited clear cognitive and behavioral improvement while consuming equivalent or larger quantities of ketogenic MCFAs. The findings of Henderson et al. (which may have lacked the statistical power to detect a change in *APOE* $\epsilon 4$ -positive subjects) do not rule out the possibility that carriers of the $\epsilon 4$ allele could show cognitive improvement if studied for longer periods of time and/or given higher doses of MCTG.

6. Conclusion

KME-induced hyperketonemia is robust, convenient, and safe, and the ester can be taken regularly as a food supplement without a need to change the habitual diet.

In treatment of the patient's long-standing AD dementia, KME-produced repeated diurnal elevations of circulating β HB levels were clearly effective, during the 20-month study, in improving behavior and cognitive and daily activity performance. The physician-caregiver noted that performance seemed to track plasma ketone concentrations, with conversation and interaction declining as levels fell toward baseline. From requiring almost constant supervision, the patient became much more self-sufficient on KME. However, generalizability of the patient's partial improvement during KME treatment (it cannot be called a "cure") remains to

be determined by appropriately designed case-control studies.

Acknowledgments

The authors thank Anne B. Pierson, MD, MPH, for helpful editorial assistance.

RESEARCH IN CONTEXT

1. Systematic review: The authors used PubMed and published lectures to assess evidence that (1) Alzheimer's disease (AD) patients exhibit impairment of glucose utilization in brain areas concerned with memory and cognition; (2) such impairment may contribute to AD's pathogenesis; and (3) induced elevation of plasma ketone bodies can bypass metabolic blocks to the brain's glucose utilization.
2. Interpretation: Evidence for impairment of glucose utilization was strong, but how much was attributable to neuronal atrophy was unclear. Although some AD patients showed modest cognitive improvement when plasma ketone concentrations were elevated by carbohydrate restriction or medium-chain triglycerides, the clinical advantage of raising plasma ketones to substantially higher levels was unknown.
3. Future directions: New evidence is provided herein that substantial increases in plasma ketone levels made possible by ingestion of a novel ketone monoester may be associated with enhanced clinical benefit in at least some AD patients. This preliminary observation requires confirmation by properly designed case-control studies.

References

- [1] Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, et al. Brain fuel metabolism, aging, and Alzheimer's disease. *Nutrition* 2011;27:3–20.
- [2] de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. *Curr Alzheimer Res* 2012;9:35–66.
- [3] Mosconi L, Berti V, McHugh P, Pupi A, de Leon MJ. A tale of two tracers: glucose metabolism and amyloid positron emission tomography imaging in Alzheimer's disease. In: Ashford JW, et al., eds. *Handbook of imaging the Alzheimer brain*. Amsterdam: IOS Press; 2011. p. 219–34.
- [4] Talbot K, Wang H-Y, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer's disease is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. *J Clin Invest* 2012;122:1316–38.
- [5] Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF Jr. Brain metabolism during fasting. *J Clin Invest* 1967;46:1589–95.
- [6] Vanlath TB, Nufert TH. Ketones: metabolism's ugly duckling. *Nutr Rev* 2003;61:327–41.
- [7] Courchesne-Loyer A, Fortier M, Tremblay-Mercier J, Chouinard-Watkins R, Roy M, Nugent S, et al. Stimulation of mild, sustained ketonemia by medium-chain triacylglycerols in healthy humans: estimated potential contribution to brain energy metabolism. *Nutrition* 2013;29:635–40.
- [8] Denton RM, Randle PJ, Bridges BJ, Cooper RH, Kerbey AL, Pask HT, et al. Regulation of mammalian pyruvate dehydrogenase. *Mol Cell Biochem* 1975;9:27–53.
- [9] Kim VI, Lee FN, Choi WS, Lee S, Youn JH. Insulin regulation of skeletal muscle PDK4 mRNA expression is impaired in acute insulin-resistant states. *Diabetes* 2006;55:2311–7.
- [10] Blomqvist G, Alvarsson M, Grill V, Von Heijne G, Ingvar M, Thorell JO, et al. Effect of acute hyperketonemia on the cerebral uptake of ketone bodies in nondiabetic subjects and IDDM patients. *Am J Physiol Endocrinol Metab* 2002;283:E20–8.
- [11] Kossoff EH, Freeman J, Turner Z, Rubenstein J. *Ketogenic diets: treatments for epilepsy and other disorders*. 5th edition. New York: Demos; 2011. p. 1–341.
- [12] Henderson ST, Vogel JL, Barr L, Garvin F, Jones JJ, Costantini LG. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. *Nutr Metab* 2009;6:31. <http://dx.doi.org/10.1186/1743-7075-6-31>.
- [13] Krikorian R, Shidler MD, Dangelo K, Couch SC, Benoit SC, Clegg DJ. Dietary ketosis enhances memory in mild cognitive impairment. *Neurobiol Aging* 2012;33:425.e19–27. <http://dx.doi.org/10.1016/j.neurobiolaging.2010.10.006>.
- [14] Clarke K, Tchabanenko K, Pawlosky R, Carter E, King MT, Musa-Veloso K, et al. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. *Regul Toxicol Pharmacol* 2012;63:401–8.
- [15] Clarke K, Tchabanenko K, Pawlosky R, Carter E, Knight NS, Murray AJ, et al. Oral 28-day and developmental toxicity studies of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. *Regul Toxicol Pharmacol* 2012;63:196–208.
- [16] Kashiwaya Y, Bergman C, Lee J-H, Wan R, King MT, Mughal MR, et al. A ketone ester diet exhibits anxiolytic and cognitive-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. *Neurobiol Aging* 2012. Pii: S0197-4580(12)00611-2. doi: 10.1016/j.neurobiolaging.2012.11.023. [Epub ahead of print].
- [17] Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, et al. Effects of β -hydroxybutyrate on cognition in memory-impaired adults. *Neurobiol Aging* 2004;25:311–4.
- [18] Tate B, McKee TD, Loureiro RM, Dumin JA, Xia W, Pojasek K, et al. Modulation of gamma-secretase for the treatment of Alzheimer's disease. *Int J Alzheimers Dis* 2012;2012:210756. <http://dx.doi.org/10.1155/2012/210756>. Epub December 19, 2012.
- [19] Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr. Ketone bodies, potential therapeutic uses. *IUBMB Life* 2001;51:241–7.
- [20] Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. *Prostaglandins Leukot Essent Fatty Acids* 2004;70:309–19.
- [21] Kerndt PR, Naughton JL. Fasting: the history, pathophysiology and complications. *West J Med* 1982;137:379–99.
- [22] Lecocq FE, McPhaul FR Jr. The effects of starvation, high fat diets, and ketone infusions on uric acid balance. *Metabolism* 1965;14:186–97.
- [23] Vining EP. Clinical efficacy of the ketogenic diet. *Epilepsy Res* 1999;37:181–90.